MyMD Pharmaceuticals (MYMD) News Today $1.33 -0.09 (-6.34%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Sarcopenia Market Anticipates Impressive Growth Trajectory Across 7MM During the Study Period (2020–2034) | DelveInsightSeptember 25, 2024 | finance.yahoo.comTNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related DeclineAugust 22, 2024 | finance.yahoo.comTNFA TNF Pharmaceuticals, Inc.August 16, 2024 | seekingalpha.comMyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.July 22, 2024 | businesswire.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024July 15, 2024 | investorplace.comMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical OfficerJune 17, 2024 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comMYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023May 17, 2024 | investorplace.comGold prices fall as rate jitters mount ahead of Fed meetingApril 30, 2024 | msn.comMorning Bid: Dollar bulls enter the China shopApril 18, 2024 | msn.comWhy Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?April 9, 2024 | investorplace.comRecursion Pharmaceuticals CEO sells over $1.16m in stockApril 7, 2024 | uk.investing.comExclusive-Software industry calls for more UK Government supportMarch 28, 2024 | msn.comMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingMarch 5, 2024 | finance.yahoo.comMyMD Pharmaceuticals Stock (NASDAQ:MYMD), Short Interest ReportFebruary 22, 2024 | benzinga.comTrading was temporarily halted for "MYMD" at 07:02 PM with a stated reason of "News pending."February 15, 2024 | marketbeat.comMyMD Pharmaceuticals down after announcing reverse stock splitFebruary 13, 2024 | msn.comMyMD Pharmaceuticals Inc Ordinary SharesDecember 8, 2023 | morningstar.comMyMD to begin Phase II trial of rheumatoid arthritis therapyDecember 7, 2023 | msn.comFive Hours Of Pain Relief? Preclinical Study Shows Promising Results With This Non-Toxic CBDOctober 20, 2023 | benzinga.comMyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory PainOctober 19, 2023 | finance.yahoo.comBaltimore pharmaceutical company faces delisting from the NasdaqOctober 18, 2023 | bizjournals.comFDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)August 14, 2023 | finance.yahoo.comMyMD Shares Surge on Positive Sarcopenia Study Results >MYMDJuly 31, 2023 | marketwatch.comMyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related FrailtyJuly 31, 2023 | finance.yahoo.comTrading was temporarily halted for "MYMD" at 08:07 AM with a stated reason of "News pending."July 31, 2023 | marketbeat.comWill MyMD Pharmaceuticals (NASDAQ:MYMD) Spend Its Cash Wisely?May 17, 2023 | finance.yahoo.comMyMD Pharmaceuticals And Charles River Present Data For Next Generation, Oral TNF-α Inhibitor MYMD-1 In Rheumatoid ArthritisMarch 22, 2023 | benzinga.comMyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid ArthritisMarch 20, 2023 | finance.yahoo.comMyMD Joins LOT Network To Protect Company And Shareholders From Patent TrollsMarch 8, 2023 | msn.comMyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed ChemicalMarch 2, 2023 | finance.yahoo.comMyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual MeetingFebruary 28, 2023 | finance.yahoo.comMyMD Announces $15 Million Offering with Existing InvestorsFebruary 21, 2023 | finance.yahoo.comADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022December 6, 2022 | finance.yahoo.comMyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug ResearchNovember 14, 2022 | finance.yahoo.comHealthcare & PharmaceuticalsSeptember 22, 2022 | reuters.comMyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanSeptember 20, 2022 | finance.yahoo.comMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD(TM) CompoundAugust 31, 2022 | stockhouse.comShort Interest in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Grows By 24.8%MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD - Get Rating) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 699,200 shares, a growth of 24.8% from the July 31st total of 560,200 shares. Approximately 2.0% of the company's shares are short sold. Based on an average daily trading volume, of 255,500 shares, the short-interest ratio is presently 2.7 days.August 30, 2022 | marketbeat.comMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ CompoundAugust 30, 2022 | finance.yahoo.comMyMD Pharmaceuticals, Inc. (MYMD)August 29, 2022 | finance.yahoo.comData Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological SciencesAugust 5, 2022 | benzinga.comIs MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders?July 29, 2022 | finance.yahoo.comNew Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsightJuly 26, 2022 | finance.yahoo.comMyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanJuly 26, 2022 | finance.yahoo.comMyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic ConditionsJuly 12, 2022 | finance.yahoo.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsJuly 7, 2022 | prnewswire.comMyMD Pharmaceuticals Inc Ordinary Shares - Stock ChartJune 18, 2022 | morningstar.comMyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanApril 5, 2022 | finance.yahoo.com Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%. Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). MYMD Media Mentions By Week MYMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYMD News Sentiment▼0.000.43▲Average Medical News Sentiment MYMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYMD Articles This Week▼00▲MYMD Articles Average Week Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AWH News INAB News AVTX News TRIB News CARA News BIOR News MTEX News SNSE News IPA News AIM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYMD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
